Hongjian Yang

Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia

Zhimin Shao, Da Pang, Hongjian Yang et al. · JAMA Oncology · 2019 · 193 citations · Full text

Medicine, Oncology, Pharmacology +17

Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial

Jiong Wu, Zefei Jiang, Zhenzhen Liu et al. · BMC Medicine · 2022 · 82 citations · Full text

Medicine, Oncology, Pharmacology +17

The pathologic characteristics of breast cancer in China and its shift during 1999–2008: A national‐wide multicenter cross‐sectional image over 10 years

Shan Zheng, Jing‐Qiao Bai, Jing Li et al. · International Journal of Cancer · 2012 · 72 citations

Medicine, Oncology, Pathology +15

Effects of Gonadotropin-Releasing Hormone Analogs on Ovarian Function Against Chemotherapy-Induced Gonadotoxic Effects in Premenopausal Women With Breast Cancer in China

Xiangyun Zong, Yang Yu, Hongjian Yang et al. · JAMA Oncology · 2021 · 42 citations · Full text

Medicine, Endocrinology, Oncology +14

Effect of cimicifuga racemosa on menopausal syndrome caused by LHRH-a in breast cancer

Chen Wang, Qiang Huang, Chenlu Liang et al. · Journal of Ethnopharmacology · 2019 · 36 citations

Medicine, Endocrinology, Oncology +15